Aushon Inks Deal with Peking University to ID Protein Biomarkers for Colorectal Cancer
February 11, 2011
Aushon Inks Deal with Peking University to ID Protein Biomarkers for Colorectal Cancer
Under the agreement, Aushon will use its protein biomarker detection platform to develop biomarkers to predict liver metastases of colorectal cancer, as well as stratification biomarkers for radio-chemotherapy patients.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Aushon Partners with LightArray to Serve Pharma Clients and Increase Access to Chinese Market
December 3, 2010 / ProteoMonitor - Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor - GMU's Petricoin Building Database That Details Activation in Cancer Protein Pathways
August 13, 2010 / ProteoMonitor - Phadia to Use Aushon 2470 Arrayer for Development of Allergen and Autoimmunity Diagnostics
June 25, 2010 / ProteoMonitor - SuppreMol to Use Protagen Biomarker Panel
August 2, 2011 / GenomeWeb Daily News